Vimarsana
Biggest News Aggregation in the World

Limb Girdle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Limb Girdle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Limb Girdle Today - Breaking & Trending Today

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference - Vimarsana News

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 10:30 am PT , and a live webcast will be...

Billy Zureikat's 'Tripping Billy' pizza with shishito peppers raises more than $42K for Muscular Dystrophy Association - Vimarsana News

Billy Zureikat's 'Tripping Billy' pizza with shishito peppers raises more than $42K for Muscular Dystrophy Association

Billy Zureikat uses his cooking prowess to raise awareness for muscular dystrophy, a disease he's struggled with for close to a decade.

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights - Vimarsana News

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy – – Advancing Phase 2 trial of EDG-5506 in Becker muscular... -Today at 08:03 am- MarketScreener

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Vimarsana News

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

BOULDER, Colo.--(BUSINESS WIRE)--Jun 26, 2023--

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Vimarsana News

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – – Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage– – EDG-5506 was well-tolerated at all doses – – Company continuing to enroll patients with BMD in the CANYON Phase 2 trial which now includes a pivotal cohort called GRAND CANYON – – Edgewise leadership to discuss ARCH findings on Tuesday, June 27 at 8:30 a.m. Eastern ...